Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD. Ramanathan RK, et al. Among authors: hezel af. Cancer. 2015 Jul 1;121(13):2193-7. doi: 10.1002/cncr.29363. Epub 2015 Mar 30. Cancer. 2015. PMID: 25827820 Free PMC article. Clinical Trial.
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
O'Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, Rossi RM, Zhu AX, Land H, Bardeesy N, Hezel AF. O'Dell MR, et al. Among authors: hezel af. Cancer Res. 2012 Mar 15;72(6):1557-67. doi: 10.1158/0008-5472.CAN-11-3596. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266220 Free PMC article.
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, Herr M, Ng K, Sheehan S, Harris DJ, Regan E, Borger DR, Iafrate AJ, Fuchs C, Ryan DP, Zhu AX. Hezel AF, et al. Br J Cancer. 2014 Jul 29;111(3):430-6. doi: 10.1038/bjc.2014.343. Epub 2014 Jun 24. Br J Cancer. 2014. PMID: 24960403 Free PMC article. Clinical Trial.
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ Jr, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. Adjei AA, et al. Among authors: hezel af. Clin Cancer Res. 2016 May 15;22(10):2368-76. doi: 10.1158/1078-0432.CCR-15-1681. Epub 2015 Dec 7. Clin Cancer Res. 2016. PMID: 26644411 Free PMC article. Clinical Trial.
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.
Leichman CG, McDonough SL, Smalley SR, Billingsley KG, Lenz HJ, Beldner MA, Hezel AF, Velasco MR, Guthrie KA, Blanke CD, Hochster HS. Leichman CG, et al. Among authors: hezel af. Clin Colorectal Cancer. 2018 Mar;17(1):e121-e125. doi: 10.1016/j.clcc.2017.10.008. Epub 2017 Oct 24. Clin Colorectal Cancer. 2018. PMID: 29233486 Free PMC article. Clinical Trial.
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.
Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N. Gurumurthy S, et al. Among authors: hezel af. Cancer Res. 2008 Jan 1;68(1):55-63. doi: 10.1158/0008-5472.CAN-07-3225. Cancer Res. 2008. PMID: 18172296 Free PMC article.
76 results